Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 268

1.

Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial.

Généreux P, Mehran R, Palmerini T, Caixeta A, Kirtane AJ, Lansky AJ, Brodie BR, Witzenbichler B, Mockel M, Guagliumi G, Peruga JZ, Dudek D, Fahy MP, Dangas G, Stone GW; HORIZONS-AMI Trial Investigators.

EuroIntervention. 2011 Dec;7(8):905-16. doi: 10.4244/EIJV7I8A144.

2.

Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.

Saltzman AJ, Stone GW, Claessen BE, Narula A, Leon-Reyes S, Weisz G, Brodie B, Witzenbichler B, Guagliumi G, Kornowski R, Dudek D, Metzger DC, Lansky AJ, Nikolsky E, Dangas GD, Mehran R.

JACC Cardiovasc Interv. 2011 Sep;4(9):1011-9. doi: 10.1016/j.jcin.2011.06.012.

3.

Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial.

Dangas G, Mehran R, Guagliumi G, Caixeta A, Witzenbichler B, Aoki J, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Rabbani LE, Parise H, Stone GW; HORIZONS-AMI Trial Investigators.

J Am Coll Cardiol. 2009 Oct 6;54(15):1438-46. doi: 10.1016/j.jacc.2009.06.021.

4.

Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.

Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW; HORIZONS-AMI Trial Investigators.

Lancet. 2009 Oct 3;374(9696):1149-59. doi: 10.1016/S0140-6736(09)61484-7. Epub 2009 Aug 28.

PMID:
19717185
5.

Bivalirudin during primary PCI in acute myocardial infarction.

Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R; HORIZONS-AMI Trial Investigators.

N Engl J Med. 2008 May 22;358(21):2218-30. doi: 10.1056/NEJMoa0708191.

6.

Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty.

Shah A, Feldman DN.

Vasc Health Risk Manag. 2012;8:115-23. doi: 10.2147/VHRM.S23491. Epub 2012 Feb 27. Review.

7.

Bleeding outcomes after routine transradial primary angioplasty for acute myocardial infarction using eptifibatide and unfractionated heparin: a single-center experience following the HORIZONS-AMI trial.

Moody WE, Chue CD, Ludman PF, Chan YK, Narayan G, Millington JM, Townend JN, Doshi SN.

Catheter Cardiovasc Interv. 2013 Sep 1;82(3):E138-47. doi: 10.1002/ccd.24703. Epub 2013 Apr 8.

PMID:
23074143
8.

Femoral vascular closure device use, bivalirudin anticoagulation, and bleeding after primary angioplasty for STEMI: results from the HORIZONS-AMI trial.

Sanborn TA, Tomey MI, Mehran R, Généreux P, Witzenbichler B, Brener SJ, Kirtane AJ, McAndrew TC, Kornowski R, Dudek D, Nikolsky E, Stone GW.

Catheter Cardiovasc Interv. 2015 Feb 15;85(3):371-9. doi: 10.1002/ccd.25663. Epub 2014 Oct 28.

PMID:
25179260
9.

Impact of transfer for primary percutaneous coronary intervention on survival and clinical outcomes (from the HORIZONS-AMI Trial).

Wöhrle J, Desaga M, Metzger C, Huber K, Suryapranata H, Guetta V, Guagliumi G, Witzenbichler B, Parise H, Mehran R, Stone GW.

Am J Cardiol. 2010 Nov 1;106(9):1218-24. doi: 10.1016/j.amjcard.2010.06.049. Epub 2010 Sep 9.

PMID:
21029816
10.

Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial.

Kornowski R, Mehran R, Dangas G, Nikolsky E, Assali A, Claessen BE, Gersh BJ, Wong SC, Witzenbichler B, Guagliumi G, Dudek D, Fahy M, Lansky AJ, Stone GW; HORIZONS-AMI Trial Investigators.

J Am Coll Cardiol. 2011 Aug 9;58(7):704-11. doi: 10.1016/j.jacc.2011.02.071.

11.

Comparison of outcomes of patients with ST-segment elevation myocardial infarction with versus without previous coronary artery bypass grafting (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] trial).

Nikolsky E, Mehran R, Yu J, Witzenbichler B, Brodie BR, Kornowski R, Brener S, Xu K, Dangas GD, Stone GW.

Am J Cardiol. 2013 May 15;111(10):1377-86. doi: 10.1016/j.amjcard.2013.01.285. Epub 2013 Mar 12.

PMID:
23465098
12.
13.

Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial.

Dangas GD, Claessen BE, Mehran R, Brener S, Brodie BR, Dudek D, Witzenbichler B, Peruga JZ, Guagliumi G, Moses JW, Lansky AJ, Xu K, Stone GW.

J Am Coll Cardiol. 2012 May 15;59(20):1752-9. doi: 10.1016/j.jacc.2011.12.042.

14.

Five-year experience with transradial coronary angioplasty in ST-segment-elevation myocardial infarction.

Ruzsa Z, Ungi I, Horváth T, Sepp R, Zimmermann Z, Thury A, Jambrik Z, Sasi V, Tóth G, Forster T, Nemes A.

Cardiovasc Revasc Med. 2009 Apr-Jun;10(2):73-9. doi: 10.1016/j.carrev.2008.07.004.

PMID:
19327668
15.

Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.

Han Y, Guo J, Zheng Y, Zang H, Su X, Wang Y, Chen S, Jiang T, Yang P, Chen J, Jiang D, Jing Q, Liang Z, Liu H, Zhao X, Li J, Li Y, Xu B, Stone GW; BRIGHT Investigators.

JAMA. 2015 Apr 7;313(13):1336-46. doi: 10.1001/jama.2015.2323.

PMID:
25775052
16.

Impact of anemia on clinical outcomes of patients with ST-segment elevation myocardial infarction in relation to gender and adjunctive antithrombotic therapy (from the HORIZONS-AMI trial).

Tsujita K, Nikolsky E, Lansky AJ, Dangas G, Fahy M, Brodie BR, Dudek D, Möckel M, Ochala A, Mehran R, Stone GW.

Am J Cardiol. 2010 May 15;105(10):1385-94. doi: 10.1016/j.amjcard.2010.01.001. Epub 2010 Apr 2.

PMID:
20451683
17.

A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.

Gibson CM, Morrow DA, Murphy SA, Palabrica TM, Jennings LK, Stone PH, Lui HH, Bulle T, Lakkis N, Kovach R, Cohen DJ, Fish P, McCabe CH, Braunwald E; TIMI Study Group.

J Am Coll Cardiol. 2006 Jun 20;47(12):2364-73.

18.

Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction.

Rozenman Y, Mehran R, Witzenbichler B, Dangas G, Desaga M, Kochman J, Nilsen DW, Finkelstein A, Mosseri M, Stone GW.

Catheter Cardiovasc Interv. 2013 Jan 1;81(1):E9-14. doi: 10.1002/ccd.24279. Epub 2012 Apr 17.

PMID:
22511592
19.
20.

Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population.

Shelton R, Eftychiou C, Somers K, Liu A, Burton-Wood N, Anderson M, Makri L, Blaxill J, McLenachan J, Wheatcroft S, Greenwood J, Blackman D.

EuroIntervention. 2013 May 20;9(1):118-24. doi: 10.4244/EIJV9I1A17.

Items per page

Supplemental Content

Write to the Help Desk